Carfilzomib
Carfilzomib is an irreversible proteasome inhibitor and antineoplastic agent that is used in treatment of refractory multiple myeloma.
| Catalog Number | T1795 |
| Alternative Name(s) | PR-171 |
| Research Area | Proteases/Proteasome|||Ubiquitination|||Autophagy|||Apoptosis |
| Molecular Formula | C40H57N5O7 |
| CAS# | 868540-17-4 |
| Purity | 99.60% |
| SMILES | O1[C@@](C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN2CCOCC2)CCc2ccccc2)CC(C)C)Cc2ccccc2)CC(C)C)(C1)C |
| Size | 100 mg |
| Supplier Page | https://www.targetmol.com/compound/Carfilzomib |
| Additional Information | https://www.targetmol.com/datasheet/T1795 |